Interleukin Genetics Inc. (ILIU) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Interleukin Genetics Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 1.08M 2M 2.86M 2.24M 2.43M
Cost of Goods Sold (COGS) incl. D&A 1.32M 1.73M 1.64M 1.44M 1.74M
COGS excluding D&A 824,144 1.31M 1.26M 1.16M 1.51M
Depreciation & Amortization Expense 494,956 426,670 385,031 282,518 229,301
Depreciation 379,503 311,217 269,578 167,065 120,035
Amortization of Intangibles 115,453 115,453 115,453 115,453 109,266
Gross Income (240,670) 262,879 1.21M 792,396 687,849
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 8.79M 5.97M 6.04M 5.46M 7.29M
Research & Development 3.21M 952,581 1.38M 1.31M 721,568
Other SG&A 5.58M 5.01M 4.67M 4.15M 6.56M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 500,000 0 0 -
EBIT after Unusual Expense 0 (500,000) 0 0 -
Non Operating Income/Expense 0 0 4,274 0 5,975
Non-Operating Interest Income 10,183 38,148 6,419 4,485 6,804
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 158,760 303,363 366,938 454,481 472,186
Gross Interest Expense 158,760 303,363 366,938 454,481 472,186
Interest Capitalized 0 0 0 0 0
Pretax Income (9.18M) (6.47M) (5.18M) (5.12M) (7.06M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 - - -
Income Tax - Current Foreign 0 0 - - -
Income Tax - Deferred Domestic 0 0 - - -
Income Tax - Deferred Foreign 0 0 - - -
Income Tax Credits 0 0 - - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (9.18M) (6.47M) (5.18M) (5.12M) (7.06M)
Minority Interest Expense 0 0 0 0 0
Net Income (9.18M) (6.47M) (5.18M) (5.12M) (7.06M)
Extraordinaries & Discontinued Operations (1.37M) 482,530 158,366 0 0
Extra Items & Gain/Loss Sale Of Assets (1.35M) 0 158,366 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (27,928) 482,530 0 0 0
Net Income After Extraordinaries (10.55M) (5.99M) (5.03M) (5.12M) (7.06M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (9.18M) (6.47M) (5.18M) (5.12M) (7.06M)
EPS (Basic) (0.29) (0.17) (0.14) (0.14) (0.08)
Basic Shares Outstanding 32.01M 35.71M 36.66M 36.75M 90.45M
EPS (Diluted) (0.29) (0.17) (0.14) (0.14) (0.08)
Diluted Shares Outstanding 32.01M 35.71M 36.66M 36.75M 90.45M
EBITDA (8.53M) (5.28M) (4.44M) (4.39M) (6.37M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Interleukin Genetics Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 1.08M 2M 2.86M 2.24M 2.43M
Cost of Goods Sold (COGS) incl. D&A 1.32M 1.73M 1.64M 1.44M 1.74M
COGS excluding D&A 824,144 1.31M 1.26M 1.16M 1.51M
Depreciation & Amortization Expense 494,956 426,670 385,031 282,518 229,301
Depreciation 379,503 311,217 269,578 167,065 120,035
Amortization of Intangibles 115,453 115,453 115,453 115,453 109,266
Gross Income (240,670) 262,879 1.21M 792,396 687,849
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 8.79M 5.97M 6.04M 5.46M 7.29M
Research & Development 3.21M 952,581 1.38M 1.31M 721,568
Other SG&A 5.58M 5.01M 4.67M 4.15M 6.56M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 500,000 0 0 -
EBIT after Unusual Expense 0 (500,000) 0 0 -
Non Operating Income/Expense 0 0 4,274 0 5,975
Non-Operating Interest Income 10,183 38,148 6,419 4,485 6,804
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 158,760 303,363 366,938 454,481 472,186
Gross Interest Expense 158,760 303,363 366,938 454,481 472,186
Interest Capitalized 0 0 0 0 0
Pretax Income (9.18M) (6.47M) (5.18M) (5.12M) (7.06M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 - - -
Income Tax - Current Foreign 0 0 - - -
Income Tax - Deferred Domestic 0 0 - - -
Income Tax - Deferred Foreign 0 0 - - -
Income Tax Credits 0 0 - - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (9.18M) (6.47M) (5.18M) (5.12M) (7.06M)
Minority Interest Expense 0 0 0 0 0
Net Income (9.18M) (6.47M) (5.18M) (5.12M) (7.06M)
Extraordinaries & Discontinued Operations (1.37M) 482,530 158,366 0 0
Extra Items & Gain/Loss Sale Of Assets (1.35M) 0 158,366 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (27,928) 482,530 0 0 0
Net Income After Extraordinaries (10.55M) (5.99M) (5.03M) (5.12M) (7.06M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (9.18M) (6.47M) (5.18M) (5.12M) (7.06M)
EPS (Basic) (0.29) (0.17) (0.14) (0.14) (0.08)
Basic Shares Outstanding 32.01M 35.71M 36.66M 36.75M 90.45M
EPS (Diluted) (0.29) (0.17) (0.14) (0.14) (0.08)
Diluted Shares Outstanding 32.01M 35.71M 36.66M 36.75M 90.45M
EBITDA (8.53M) (5.28M) (4.44M) (4.39M) (6.37M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
